FDA Investigator Sean R Bryd
Sean R Bryd has inspections in 6 countries as of 29 Sep 2023. Sean R Bryd has collaborated with a combined 3506 experts on various inspections, contributing to compliance and improvement across diverse sectors.
Investigator Details
Number of Inspected Sites:
13
Last Inspection Date:
29 Sep 2023
Investigator Role:
FDA Investigation Participant
Redica ID:
Country:
Belgium,
United States of America,
France,
Italy,
Canada,
Hungary
Co-Investigator(s):
Anissa M Cheung,
Anita Verma,
Ann L Demarco,
Ann Marie Montemurro,
Arduino Frankovic,
Ashley L Reiber,
Ava M Bowman,
Barbara M Frazier,
Benjamin J Smith,
Bradley Dworak, PhD,
Brentley S Collins,
Brian D Nicholson,
Burnell M Henry,
Carrie Ann Plucinski,
Cassandra Overking,
CDR Donald Ertel,
CDR Jeremy L Wally, PhD,
Chad R Burger,
Charles M Spyr,
Cheng H Yen,
Christian D Lynch (CDL),
Christina D Lynch,
Christina J Sauder, PhD,
Christine A Harman, PhD,
Claire M Minden,
Constantin Y Philopoulos,
Cristina Ausin Moreno, PhD,
Cristina Ausin Moreoo, PhD,
Cynthia Jim, CSO,
Daniel C Kearns,
Darla J Christopher,
Daryl A Dewoskin,
David A Paterson,
David Perkins,
Deborah J Parris,
Deborah M Trout,
Debra I Love,
Devaughn Edwards,
Diana Kouiavskaia,
Diane L Raccasi,
Dino Feigelstock (DF), PhD,
Dmitriy V Volokhov, PhD,
Donald L Lech,
Dr. Andrew Shroke,
Dr. Gang Wang, PhD,
Eboni S Funderburk,
Edmund F Mrak, Jr,
Edwin Jao,
Eileen A Liu,
Eliezar Ramos,
Emest F Bizjak,
Emilie E Kahn,
Emily J Orban,
Enrico Joset Mangahis,
Eric Peng,
Esther C Broner, PhD,
Gene D Arcy,
Gregory Price,
Haruhiko Murata,
Hector A Carrero,
Helen B Ricalde,
Humera Khan,
Humera T Khan,
Hyesuk Kong,
Hyung Yul Lee,
Ifueko Osemwota,
J David Doleski,
Jacqueline Mdiaz Albertini,
James A Lane,
James C Maclaughlin,
James E Keller, PhD,
James L Kenney, DSc,
James M Simpson,
James R Evans,
James T Mccoy,
Jaqueline Diaz Albertini,
Jason F Chancey,
Jeanne M Morris,
Jeffrey A Sommers,
Jeffrey D Meng,
Jennifer L Bridgewater,
Jennifer L Schmidt,
Joan A Loreng,
Joan Johnson,
John F Cipollo,
John M Mcinnis,
John M Seale,
John P Mistler,
Jon P Antoniou,
Joseph George,
Joslyn K Brunelle, PhD,
Jude C Dikes,
Julie D Bringger,
Jun Park, PhD,
Kevin P Foley,
Kirsten L Vadheim, PhD,
Kristina J Donohue,
Kula N Jha,
Larry K Austin,
Laura Fontan, MS,
Laurel A Beer,
Laurie P Norwood,
LCDR Debra Emerson,
LCDR Randall L Morris,
LCDR Sean Byrd,
Leslie D Wagner,
Lewis K Antwi,
Linda Thai,
Logan T Williams,
Lori P Peters,
Lori S Lawless,
Marc S Neubauer,
Maria Cruz Fisher,
Maria I Cruz Fisher,
Marian Majors,
Mariza M Jafary,
Martha T Olone,
Megan A Haggerty,
Meisha R Sampson,
Meisha Waters,
Michael Shanks, MS,
Michele L Forster, PhD,
Michele L Glendenning,
Michele Perry Williams,
Mihaly S Ligmond,
Muna Algharibeh,
Muna Alghribeh,
Nancy T Waites,
Nawab A Siddiqui,
Nicholas L Paulin,
Nicole K Trudel,
Olno Folgolstock,
Omotunde O Osunsanmi,
Pankaj H Amin,
Patricia A Morrow,
Patricia Fhughes Troost,
Patsy J Domingo,
Paul W Keller,
Paula A Trost,
Peng Zhou,
Pote Amin,
Prabhu P Raju,
Priscilla M Pastrana,
Qing Joanna Zhou, PhD,
Rabia Ballica, PhD,
Ralph A Erickson,
Rebecca E Dombrowski,
Rebecca K Olin,
Regina Gibson Melton,
Reyes Candau Chacon, PhD,
Richard Heath Coats,
Richard T Riggie,
Robert Barbosa,
Robert C Coleman,
Robert M Barbosa,
Robert W Jennings,
Robin Levis, PhD,
Roger F Zabinski,
Rona A Leblanc,
Ronald E Lundquist,
Ronald T Nowalk,
Rose M Ashley,
Russell K Riley,
Samuel W Labinjo,
Sandra A Boyd,
Sarah B Tanksley,
Sarah M Meng,
Sarah M Napier,
Sargum C Sood,
Scott E Norris,
Scott R Nichols, PhD,
Scott T Ballard,
Shuang Tang,
Sidney B Priesmeyer,
Simone E Pitts,
Sneha S Patel,
Stacey S Degarmo,
Stephen D Brown,
Steven C Derrick,
Steven P Donald,
Susan M Jackson,
Susan P Bruederle,
Susan Yu,
Tim S Roecklein,
Timothy J Schmidt,
Tina Buecklein,
Tina S Roecklein,
Travis S Bradley,
Troy C Quander,
Unnee Ranjan,
Vaishali J Patel,
Wayne E Seifert,
Wei Wang, PhD,
Yanming An, PhD,
Yonggang Wang, PhD,
Zhihao Qiu (Peter), PhD
Sean R Bryd's Documents
Publish Date | Document Type | Title |
---|---|---|
July, 2008 | FDA 483 | Sanofi Pasteur Limited - Form 483, 2008-07-24 |
July, 2008 | EIR | Sanofi Pasteur Limited - EIR, 2008-07-24 |
February, 2012 | EIR | Catalent Indiana, LLC - EIR, 2012-02-24 |
Experience Redica Systems’ NEW investigator profiles and dashboards
Redica Systems customers get access to over 1,400 FDA Investigator profiles, containing powerful analysis like:
- Total inspections conducted
- 483 rate
- OAI rate
- Warning Letter rate
- Inspections by Industry, Scope, and Inspection Reason
- And much more
Investigator Profiles are not sold as on-demand documents. If you’d like to see one, fill out the form below to connect with our Sales Team and get it in your inbox as little as 24 hours.
![FDA Investigator Profile Icon](https://redica.com/document-store/images/InspectorProfile.png)
Talk to sales to access our investigator profiles
Loading...
Investigator Profiles Are Just the Tip of the Iceberg
Becoming a Redica Systems customer not only provides you with unlimited access to profiles similar to the one above for every current and former FDA Investigator, but also grants you access to:
Inspection Intelligence
- Pre-Approval Inspection (PAI) trends
- The ability to filter nearly any FDA enforcement action by GxP labels like GMP, GCP, etc.
- Latest 483s: see what the trends are across all FDA Investigators
- CFR Heatmap: Citations aggregated by Subpart by Year
Vendor Intelligence
- Full inspection histories for your vendors down to the specific site level
- All of the functionality mentioned above but isolated to just your vendors
Regulatory Intelligence
- Zero in on the trends for a specific agency/regulator (ex. FDA, MHRA, EMA, Health Canada)
- All the latest "Signals" from agencies around the world, segmented by Country, Type (ex. Guidance, Decree...), Category (ex. Rules/Regulations/Guidance, News, Reports...), Theme (ex. Cell and Gene Therapy, AI...), and more